Minimally invasive treatments for thyroid cancer
Multicenter International Prospective Analysis on Minimally Invasive Treatments of the Thyroid (MIPA- MITT) of of Micropapillary Thyroid Carcinoma
This study is testing whether less invasive treatments for small thyroid cancers can safely replace surgery and improve patients' quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 270 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | European Institute of Oncology Academic / other |
| Locations | 1 site (Milan) |
| Trial ID | NCT06333587 on ClinicalTrials.gov |
What this trial studies
This study focuses on the use of minimally invasive treatments, specifically image-guided thermal ablations, as an alternative to surgery for patients diagnosed with Papillary Thyroid Microcarcinoma (PTMC). It aims to establish a prospective registry to validate the safety and efficacy of these treatments while collecting long-term results from a large cohort of patients. The approach is designed to minimize complications and improve quality of life by precisely targeting the tumor while sparing surrounding thyroid tissue.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years with a cytologically proven diagnosis of Papillary Thyroid Microcarcinoma suitable for minimally invasive treatments.
Not a fit: Patients with tumors larger than 1 cm or those with other types of thyroid cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this could provide a less invasive treatment option for patients with Papillary Thyroid Microcarcinoma, leading to fewer complications and improved quality of life.
How similar studies have performed: Other studies have shown promising results with similar minimally invasive approaches, indicating potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients \> 18years * Patients with diagnosis of papillary thyroid microcarcinoma, citologically proven, suitable for MITT. * Written informed consent must be signed and dated by the patient and the investigator prior to inclusion. * Patients must be accessible for follow-up Exclusion Criteria: * Tumors \> 1 cm, other citological type, refusal of MITT, unsuitable for MITT, unmanageable coagulative disorders * Patients with psychiatric, addictive, or any disorder, which compromises ability to give informed consent for participation in this study
Where this trial is running
Milan
- European Institute of Oncology — Milan, Italy (Recruiting)
Study contacts
- Principal investigator: Giovanni Mauri — European Institute of Oncology
- Study coordinator: Giovanni Mauri
- Email: giovanni.mauri@ieo.it
- Phone: +390294372691
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.